Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
The valuation ratios exhibit a synchronized cyclical pattern characterized by a period of expansion through the first half of 2024, a sharp contraction in the first quarter of 2025, and a subsequent recovery trending upward through September 2026. This correlation across all metrics suggests that the valuation fluctuations are driven by systemic market sentiment or broad company-wide valuation adjustments rather than isolated changes in a single financial component.
- Price to Earnings (P/E) Ratio
- The P/E ratio demonstrates significant volatility, beginning at 28.15 in April 2022 and ascending to a peak of 37.81 by June 2024. A substantial correction occurred between December 2024 and March 2025, where the ratio dropped to its lowest point of 24.55. Following this trough, a strong recovery phase is observed, with the ratio climbing back to 36.52 by September 2026.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio closely mirrors the trajectory of the P/E ratio. It rose from 21.84 in early 2022 to a maximum of 32.66 in June 2024. Similar to the earnings multiple, a sharp decline is evident in March 2025, reaching 21.64, before rebounding to 30.50 by the end of the observed period in September 2026.
- Price to Sales (P/S) Ratio
- The P/S ratio remained relatively stable compared to earnings-based metrics but still followed the general trend. After fluctuating between 4.05 and 5.55 through 2024, the ratio hit a minimum of 3.73 in March 2025. A consistent upward trend followed, returning to a high of 5.45 by September 2026.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio shows a gradual decline from its early 2022 peak of 5.47, followed by a marked contraction to 3.24 in March 2025. This represents the most significant percentage decrease relative to the starting value among all ratios. The ratio subsequently recovered to 4.72 by September 2026, though it remained below its 2022 highs.
Overall, the data indicates a period of valuation compression centered around the first quarter of 2025, followed by a robust rebound. The tight alignment between P/E and P/OP ratios suggests that operating margins remained relatively consistent relative to net income during these valuation swings.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Earnings (P/E)
| Sep 26, 2026 | Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 370,515,868 | 369,747,286 | 371,621,465 | 371,484,244 | 375,708,059 | 377,612,121 | 377,493,912 | 377,261,182 | 382,500,265 | 381,995,566 | 381,716,323 | 381,312,268 | 386,372,321 | 385,949,773 | 385,721,286 | 385,430,077 | 392,195,557 | 391,788,962 | 391,462,000 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Net income attributable to Thermo Fisher Scientific Inc. (in millions) | 1,721) | 1,736) | 1,651) | 1,964) | 1,616) | 1,617) | 1,507) | 1,829) | 1,630) | 1,548) | 1,328) | 1,630) | 1,715) | 1,361) | 1,289) | 1,576) | 1,495) | 1,664) | 2,215) | ||||||
| Earnings per share (EPS)2 | 19.09 | 18.84 | 18.43 | 18.05 | 17.48 | 17.43 | 17.26 | 16.79 | 16.04 | 16.29 | 15.81 | 15.72 | 15.38 | 14.82 | 15.62 | 18.03 | 17.93 | 18.99 | 19.42 | ||||||
| Share price1, 3 | 697.00 | 574.30 | 469.21 | 520.12 | 567.39 | 463.04 | 423.55 | 537.83 | 557.92 | 615.69 | 572.38 | 560.49 | 454.74 | 548.64 | 546.38 | 550.95 | 495.55 | 590.26 | 546.68 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/E ratio4 | 36.52 | 30.48 | 25.46 | 28.82 | 32.45 | 26.56 | 24.55 | 32.03 | 34.78 | 37.81 | 36.21 | 35.65 | 29.57 | 37.01 | 34.99 | 30.55 | 27.64 | 31.09 | 28.15 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | 48.88 | 68.64 | 97.96 | 94.06 | 159.78 | 92.57 | 77.73 | 79.59 | 69.16 | 62.04 | 48.26 | 63.84 | 38.27 | 30.55 | 34.43 | 22.62 | 19.16 | 19.44 | 21.64 | ||||||
| Amgen Inc. | 27.56 | 25.22 | 22.82 | 25.81 | 24.59 | 23.15 | 25.49 | 38.24 | 40.68 | 53.65 | 44.38 | 23.14 | 18.09 | 16.31 | 16.18 | 19.56 | 21.00 | 20.03 | 22.23 | ||||||
| Bristol-Myers Squibb Co. | 13.58 | 14.27 | 17.01 | 17.30 | 15.38 | 17.46 | 18.29 | — | — | — | — | 12.27 | 13.01 | 15.93 | 19.43 | 23.97 | 23.71 | 24.14 | 25.64 | ||||||
| Danaher Corp. | 37.99 | 31.43 | 37.32 | 40.93 | 44.52 | 39.84 | 36.51 | 38.12 | 48.49 | 45.39 | 42.59 | 39.09 | 24.76 | 29.99 | 25.00 | 25.65 | 26.65 | 32.73 | 32.15 | ||||||
| Eli Lilly & Co. | 46.86 | 41.23 | 34.82 | 47.45 | 43.36 | 43.95 | 67.76 | 77.63 | 96.05 | 109.42 | 120.94 | 135.24 | 110.43 | 76.21 | 65.16 | 50.08 | 55.53 | 51.05 | 45.29 | ||||||
| Gilead Sciences Inc. | — | — | 18.06 | 21.54 | 18.18 | 21.68 | 20.62 | 296.57 | 925.87 | 89.29 | 166.76 | 16.17 | 17.10 | 17.88 | 17.75 | 22.68 | 29.30 | 18.66 | 17.25 | ||||||
| Johnson & Johnson | 38.56 | 29.70 | 25.87 | 21.66 | 18.51 | 18.02 | 17.14 | 26.92 | 27.19 | 10.11 | 9.46 | 10.73 | 10.12 | 33.35 | 33.43 | 22.97 | 23.52 | 24.98 | 23.95 | ||||||
| Merck & Co. Inc. | 151.11 | 99.98 | 31.27 | 16.79 | 11.00 | 12.30 | 11.98 | 13.49 | 20.98 | 20.73 | 140.05 | 893.99 | 56.85 | 86.53 | 22.92 | 19.21 | 16.41 | 13.36 | 15.70 | ||||||
| Pfizer Inc. | 42.39 | 33.42 | 20.12 | 19.83 | 14.06 | 13.09 | 17.22 | 18.42 | 37.00 | — | — | 73.42 | 16.60 | 9.42 | 7.44 | 7.58 | 8.81 | 9.56 | 11.11 | ||||||
| Regeneron Pharmaceuticals Inc. | 19.93 | 17.56 | 16.27 | 18.19 | 15.03 | 13.29 | 13.65 | 17.76 | 19.79 | 27.88 | 26.78 | 25.99 | 22.35 | 19.48 | 19.77 | 19.68 | 14.98 | 11.67 | 9.15 | ||||||
| Vertex Pharmaceuticals Inc. | 33.85 | 27.54 | 24.83 | 31.58 | 29.11 | 26.43 | — | — | — | — | 26.34 | 30.42 | 28.09 | 27.49 | 27.34 | 23.02 | 24.62 | 23.12 | 26.50 | ||||||
Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
EPS
= (Net income attributable to Thermo Fisher Scientific Inc.Q3 2026
+ Net income attributable to Thermo Fisher Scientific Inc.Q2 2026
+ Net income attributable to Thermo Fisher Scientific Inc.Q1 2026
+ Net income attributable to Thermo Fisher Scientific Inc.Q4 2025)
÷ No. shares of common stock outstanding
= (1,721,000,000 + 1,736,000,000 + 1,651,000,000 + 1,964,000,000)
÷ 370,515,868 = 19.09
3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/E ratio = Share price ÷ EPS
= 697.00 ÷ 19.09 = 36.52
5 Click competitor name to see calculations.
The financial data indicates a period of significant volatility in valuation multiples, characterized by an initial contraction in earnings followed by a steady recovery and subsequent expansion in the price-to-earnings (P/E) ratio.
- Earnings per Share (EPS) Performance
- A cyclical trend is observed in earnings, with EPS declining from a peak of 19.42 USD in April 2022 to a trough of 14.82 USD by July 2023. Following this decline, a consistent upward trajectory is evident, with earnings recovering to 19.09 USD by September 2026, effectively returning to the levels seen at the start of the analyzed period.
- Price-to-Earnings (P/E) Ratio Fluctuations
- The P/E ratio exhibited substantial variance, peaking at 37.81 in June 2024 and reaching a low of 24.55 in December 2024. A notable divergence occurred in mid-2023, where the P/E ratio increased to 37.01 despite falling EPS, suggesting that market pricing remained elevated relative to the decline in actual earnings during that window.
- Valuation Compression and Expansion
- A period of valuation compression is identified between December 2023 and December 2024, where the P/E ratio fell from 35.65 to 24.55. This was primarily driven by a decrease in share price that outpaced the growth in EPS. Conversely, a sharp valuation expansion occurred throughout 2026, with the P/E ratio rising from 25.46 in March to 36.52 in September, coinciding with the share price reaching a period high of 697.00 USD.
- Correlation Analysis
- The data reveals that while EPS growth remained steady from 2024 through 2026, the P/E ratio was more heavily influenced by share price volatility. The final quarter of the data shows a strong positive correlation between the rising share price and an expanding P/E multiple, indicating increased investor optimism or a higher premium assigned to future earnings growth.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Operating Profit (P/OP)
| Sep 26, 2026 | Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 370,515,868 | 369,747,286 | 371,621,465 | 371,484,244 | 375,708,059 | 377,612,121 | 377,493,912 | 377,261,182 | 382,500,265 | 381,995,566 | 381,716,323 | 381,312,268 | 386,372,321 | 385,949,773 | 385,721,286 | 385,430,077 | 392,195,557 | 391,788,962 | 391,462,000 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Operating income (in millions) | 2,263) | 2,087) | 1,863) | 2,255) | 1,941) | 1,834) | 1,716) | 2,016) | 1,838) | 1,820) | 1,663) | 1,854) | 1,864) | 1,578) | 1,563) | 1,861) | 1,710) | 2,001) | 2,821) | ||||||
| Operating profit per share2 | 22.85 | 22.03 | 21.24 | 20.85 | 19.98 | 19.61 | 19.58 | 19.45 | 18.76 | 18.85 | 18.23 | 17.99 | 17.77 | 17.39 | 18.50 | 21.78 | 23.13 | 24.60 | 25.03 | ||||||
| Share price1, 3 | 697.00 | 574.30 | 469.21 | 520.12 | 567.39 | 463.04 | 423.55 | 537.83 | 557.92 | 615.69 | 572.38 | 560.49 | 454.74 | 548.64 | 546.38 | 550.95 | 495.55 | 590.26 | 546.68 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/OP ratio4 | 30.50 | 26.07 | 22.09 | 24.94 | 28.40 | 23.62 | 21.64 | 27.65 | 29.74 | 32.66 | 31.40 | 31.16 | 25.59 | 31.55 | 29.54 | 25.30 | 21.43 | 23.99 | 21.84 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | 23.81 | 25.67 | 23.23 | 26.37 | 42.20 | 31.76 | 32.37 | 37.26 | 25.63 | 26.99 | 22.62 | 24.34 | 16.55 | 15.26 | 16.15 | 14.78 | 14.52 | 14.12 | 14.57 | ||||||
| Amgen Inc. | 20.52 | 19.30 | 16.84 | 21.92 | 19.86 | 18.71 | 20.31 | 21.55 | 27.68 | 27.12 | 23.97 | 19.69 | 15.45 | 13.71 | 14.25 | 13.40 | 14.89 | 14.08 | 15.88 | ||||||
| Bristol-Myers Squibb Co. | 10.86 | 11.30 | 12.42 | 12.20 | 10.25 | 11.07 | 13.65 | — | — | — | — | 13.53 | 14.14 | 16.24 | 17.09 | 18.29 | 17.79 | 18.62 | 20.32 | ||||||
| Danaher Corp. | 31.53 | 24.54 | 28.93 | 31.54 | 33.80 | 30.79 | 28.49 | 30.56 | 39.52 | 38.14 | 37.52 | 35.64 | 23.61 | 27.01 | 21.31 | 20.97 | 20.71 | 25.91 | 26.48 | ||||||
| Eli Lilly & Co. | 37.05 | 32.74 | 27.92 | 37.24 | 34.60 | 35.19 | 53.43 | 63.73 | 79.30 | 88.66 | 99.34 | 109.75 | 93.27 | 69.42 | 59.60 | 43.88 | 46.48 | 39.20 | 36.49 | ||||||
| Gilead Sciences Inc. | — | — | 16.05 | 18.29 | 14.06 | 17.00 | 14.96 | 85.65 | 143.05 | 36.80 | 51.26 | 12.05 | 12.16 | 11.57 | 11.21 | 14.21 | 16.27 | 11.02 | 10.78 | ||||||
| Johnson & Johnson | 25.09 | 24.10 | 21.40 | 22.95 | 19.83 | 19.04 | 17.74 | 18.20 | 18.65 | 17.54 | 16.96 | 17.78 | 15.69 | 18.91 | 18.26 | 17.62 | 19.64 | 20.45 | 21.06 | ||||||
| Merck & Co. Inc. | 67.93 | 49.74 | 23.37 | 14.44 | 9.67 | 10.57 | 10.37 | 11.60 | 18.67 | 18.41 | 75.94 | 138.56 | 33.75 | 44.67 | 18.53 | 15.55 | 13.85 | 11.72 | 14.29 | ||||||
| Pfizer Inc. | 12.54 | 10.48 | 10.37 | 10.82 | 10.07 | 9.49 | 11.27 | 11.92 | 27.24 | — | — | 121.63 | 17.49 | 9.17 | 6.74 | 6.80 | 7.82 | 9.11 | 11.49 | ||||||
| Regeneron Pharmaceuticals Inc. | 19.73 | 19.78 | 19.83 | 22.90 | 18.65 | 15.42 | 16.03 | 19.63 | 23.18 | 30.86 | 26.82 | 25.39 | 21.13 | 19.32 | 18.68 | 18.01 | 12.91 | 9.68 | 7.98 | ||||||
| Vertex Pharmaceuticals Inc. | 31.27 | 25.40 | 23.01 | 29.92 | 26.79 | 24.50 | — | — | — | — | 25.25 | 28.74 | 25.14 | 23.33 | 22.03 | 17.75 | 19.41 | 18.11 | 22.13 | ||||||
Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Operating profit per share
= (Operating incomeQ3 2026
+ Operating incomeQ2 2026
+ Operating incomeQ1 2026
+ Operating incomeQ4 2025)
÷ No. shares of common stock outstanding
= (2,263,000,000 + 2,087,000,000 + 1,863,000,000 + 2,255,000,000)
÷ 370,515,868 = 22.85
3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 697.00 ÷ 22.85 = 30.50
5 Click competitor name to see calculations.
An analysis of the valuation metrics from April 2022 through September 2026 reveals a period of significant volatility in both share price and operating profitability, leading to fluctuating price-to-operating profit (P/OP) multiples. The overall trend indicates a transition from a period of declining operational efficiency to a steady recovery, accompanied by a cyclical expansion and contraction of the valuation multiple.
- Operating Profitability Trends
- Operating profit per share exhibited a pronounced U-shaped trajectory. A steady decline was observed from April 2022, where profit per share stood at 25.03 US$, reaching a trough of 17.39 US$ in July 2023. Following this low point, a consistent recovery phase began, characterized by incremental gains that culminated in a value of 22.85 US$ by September 2026. This recovery indicates a gradual restoration of operational margins over the latter half of the analyzed period.
- Share Price Volatility
- The share price demonstrated substantial variance, with significant swings occurring independently of the profit trend. A notable decline is observed between December 2023 (560.49 US$) and March 2025, where the price reached a period low of 423.55 US$. However, a strong bullish trend emerged thereafter, with the price ascending to a peak of 697.00 US$ by September 2026, representing the highest valuation in the sequence.
- Price to Operating Profit (P/OP) Analysis
- The P/OP ratio fluctuated between a low of 21.43 in October 2022 and a peak of 32.66 in June 2024. The ratio experienced significant expansion during 2023 and early 2024, largely driven by a combination of declining operating profits and a resilient share price, which suggests a period where the market maintained high expectations despite weakening operational performance. A subsequent compression of the multiple occurred toward March 2025, coinciding with the share price trough, before the ratio expanded again to 30.50 by September 2026 as the share price surged more rapidly than the growth in operating profit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Sales (P/S)
| Sep 26, 2026 | Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 370,515,868 | 369,747,286 | 371,621,465 | 371,484,244 | 375,708,059 | 377,612,121 | 377,493,912 | 377,261,182 | 382,500,265 | 381,995,566 | 381,716,323 | 381,312,268 | 386,372,321 | 385,949,773 | 385,721,286 | 385,430,077 | 392,195,557 | 391,788,962 | 391,462,000 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Revenues (in millions) | 12,137) | 11,994) | 11,005) | 12,215) | 11,122) | 10,855) | 10,364) | 11,395) | 10,598) | 10,541) | 10,345) | 10,886) | 10,574) | 10,687) | 10,710) | 11,450) | 10,677) | 10,970) | 11,818) | ||||||
| Sales per share2 | 127.80 | 125.32 | 121.62 | 119.94 | 116.41 | 114.43 | 113.64 | 113.66 | 110.77 | 110.85 | 111.32 | 112.39 | 112.38 | 112.77 | 113.57 | 116.53 | 112.61 | 109.29 | 105.05 | ||||||
| Share price1, 3 | 697.00 | 574.30 | 469.21 | 520.12 | 567.39 | 463.04 | 423.55 | 537.83 | 557.92 | 615.69 | 572.38 | 560.49 | 454.74 | 548.64 | 546.38 | 550.95 | 495.55 | 590.26 | 546.68 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/S ratio4 | 5.45 | 4.58 | 3.86 | 4.34 | 4.87 | 4.05 | 3.73 | 4.73 | 5.04 | 5.55 | 5.14 | 4.99 | 4.05 | 4.87 | 4.81 | 4.73 | 4.40 | 5.40 | 5.20 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | 7.66 | 6.73 | 5.67 | 6.50 | 6.40 | 5.97 | 5.68 | 6.04 | 6.38 | 6.02 | 5.32 | 5.72 | 4.52 | 4.74 | 4.60 | 4.61 | 4.44 | 4.28 | 4.76 | ||||||
| Amgen Inc. | 6.99 | 6.08 | 5.02 | 5.66 | 4.99 | 4.57 | 4.61 | 4.88 | 5.53 | 5.68 | 5.93 | 5.78 | 5.34 | 5.14 | 5.14 | 5.17 | 5.85 | 5.35 | 5.21 | ||||||
| Bristol-Myers Squibb Co. | 2.51 | 2.69 | 2.55 | 2.53 | 1.93 | 1.85 | 2.08 | 2.36 | 2.38 | 2.20 | 1.99 | 2.19 | 2.40 | 2.81 | 3.10 | 3.29 | 3.39 | 3.39 | 3.41 | ||||||
| Danaher Corp. | 6.42 | 5.01 | 5.56 | 6.02 | 6.43 | 5.66 | 5.77 | 6.23 | 7.95 | 8.10 | 7.90 | 7.76 | 5.63 | 6.77 | 5.76 | 5.79 | 5.66 | 6.59 | 6.68 | ||||||
| Eli Lilly & Co. | 14.95 | 13.82 | 12.18 | 15.03 | 13.44 | 11.39 | 15.36 | 18.25 | 19.67 | 20.64 | 20.66 | 20.77 | 17.18 | 16.78 | 13.38 | 10.96 | 11.46 | 9.99 | 9.47 | ||||||
| Gilead Sciences Inc. | 6.88 | 5.44 | 5.69 | 6.34 | 5.16 | 4.76 | 4.31 | 4.98 | 4.18 | 3.41 | 2.97 | 3.40 | 3.69 | 3.61 | 3.70 | 3.86 | 3.64 | 2.84 | 2.86 | ||||||
| Johnson & Johnson | 6.25 | 6.38 | 5.65 | 6.16 | 5.04 | 4.51 | 4.19 | 4.26 | 4.55 | 4.44 | 4.25 | 4.43 | 4.01 | 4.84 | 4.60 | 4.34 | 4.69 | 4.80 | 5.00 | ||||||
| Merck & Co. Inc. | 5.50 | 4.77 | 4.25 | 4.71 | 3.26 | 3.17 | 3.27 | 3.60 | 4.03 | 4.56 | 5.26 | 5.43 | 4.42 | 4.62 | 5.16 | 4.71 | 4.25 | 3.87 | 4.12 | ||||||
| Pfizer Inc. | 2.69 | 2.27 | 2.38 | 2.46 | 2.20 | 2.20 | 2.17 | 2.32 | 2.60 | 3.00 | 2.86 | 2.61 | 2.51 | 2.58 | 2.32 | 2.37 | 2.63 | 2.77 | 3.00 | ||||||
| Regeneron Pharmaceuticals Inc. | 5.68 | 4.89 | 4.82 | 5.71 | 4.83 | 4.17 | 4.36 | 5.52 | 6.65 | 8.93 | 7.89 | 7.84 | 6.81 | 6.61 | 6.69 | 7.01 | 5.87 | 4.66 | 4.40 | ||||||
| Vertex Pharmaceuticals Inc. | 10.39 | 9.64 | 8.82 | 10.40 | 9.13 | 8.42 | 10.41 | 10.78 | 12.12 | 12.35 | 10.39 | 11.16 | 10.10 | 9.73 | 9.68 | 8.56 | 9.26 | 8.85 | 8.17 | ||||||
Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Sales per share
= (RevenuesQ3 2026
+ RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025)
÷ No. shares of common stock outstanding
= (12,137,000,000 + 11,994,000,000 + 11,005,000,000 + 12,215,000,000)
÷ 370,515,868 = 127.80
3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= 697.00 ÷ 127.80 = 5.45
5 Click competitor name to see calculations.
The financial data reveals a period of significant valuation volatility characterized by fluctuating Price-to-Sales (P/S) ratios against a backdrop of consistent, long-term growth in sales per share. While the fundamental revenue generation per share exhibited a steady upward trajectory, the market valuation experienced several distinct cycles of expansion and contraction.
- Sales per Share Trend
- A consistent growth pattern is observed in sales per share, rising from 105.05 US$ in April 2022 to 127.80 US$ by September 2026. Although a period of stagnation occurred between late 2023 and mid-2024, where values hovered around 110.00 to 112.00 US$, the metric resumed a firm ascent starting in 2025, indicating a sustained improvement in the underlying revenue base.
- Share Price Volatility
- The share price demonstrated substantial variance, ranging from a low of 423.55 US$ in March 2025 to a peak of 697.00 US$ in September 2026. Significant price corrections were noted in October 2022 and again throughout the first half of 2025, followed by aggressive recoveries in late 2025 and throughout 2026.
- Price-to-Sales (P/S) Ratio Analysis
- The P/S ratio fluctuated between a minimum of 3.73 and a maximum of 5.55. Valuation peaks occurred in July 2022 (5.40), June 2024 (5.55), and September 2026 (5.45). Conversely, significant valuation contractions were observed in September 2023 (4.05) and December 2024 (3.73). These fluctuations indicate that the P/S ratio was primarily driven by changes in investor sentiment and share price movements rather than by changes in sales performance.
- Valuation Correlation
- An inverse relationship is occasionally observed between the P/S ratio and sales growth; for example, during the period between December 2024 and March 2026, the P/S ratio reached some of its lowest levels (3.73 to 3.86) despite sales per share continuing to climb. This suggests a period of valuation compression where the market paid less for each dollar of revenue. The trend reversed sharply by September 2026, as the P/S ratio returned to 5.45, coinciding with a surge in share price to its highest recorded level.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Book Value (P/BV)
| Sep 26, 2026 | Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 370,515,868 | 369,747,286 | 371,621,465 | 371,484,244 | 375,708,059 | 377,612,121 | 377,493,912 | 377,261,182 | 382,500,265 | 381,995,566 | 381,716,323 | 381,312,268 | 386,372,321 | 385,949,773 | 385,721,286 | 385,430,077 | 392,195,557 | 391,788,962 | 391,462,000 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity (in millions) | 54,761) | 52,679) | 51,934) | 53,407) | 51,018) | 50,512) | 49,390) | 49,584) | 48,992) | 47,432) | 45,516) | 46,735) | 45,328) | 43,752) | 42,257) | 43,978) | 43,549) | 42,293) | 40,956) | ||||||
| Book value per share (BVPS)2 | 147.80 | 142.47 | 139.75 | 143.77 | 135.79 | 133.77 | 130.84 | 131.43 | 128.08 | 124.17 | 119.24 | 122.56 | 117.32 | 113.36 | 109.55 | 114.10 | 111.04 | 107.95 | 104.62 | ||||||
| Share price1, 3 | 697.00 | 574.30 | 469.21 | 520.12 | 567.39 | 463.04 | 423.55 | 537.83 | 557.92 | 615.69 | 572.38 | 560.49 | 454.74 | 548.64 | 546.38 | 550.95 | 495.55 | 590.26 | 546.68 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/BV ratio4 | 4.72 | 4.03 | 3.36 | 3.62 | 4.18 | 3.46 | 3.24 | 4.09 | 4.36 | 4.96 | 4.80 | 4.57 | 3.88 | 4.84 | 4.99 | 4.83 | 4.46 | 5.47 | 5.23 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | 229.63 | 102.40 | 58.73 | 48.87 | 36.12 | 29.97 | 20.61 | 20.62 | 19.68 | 15.52 | 16.06 | 16.76 | 16.59 | ||||||
| Amgen Inc. | 18.03 | 18.86 | 19.37 | 22.99 | 17.91 | 20.63 | 24.36 | 26.61 | 22.86 | 28.34 | 33.25 | 24.94 | 17.87 | 19.19 | 23.95 | 35.01 | 39.30 | 54.46 | 138.87 | ||||||
| Bristol-Myers Squibb Co. | 5.36 | 5.94 | 6.17 | 6.61 | 5.01 | 5.06 | 5.70 | 6.98 | 6.60 | 6.01 | 5.49 | 3.35 | 3.72 | 3.97 | 4.46 | 4.88 | 4.85 | 4.90 | 5.07 | ||||||
| Danaher Corp. | 3.07 | 2.39 | 2.60 | 2.82 | 3.05 | 2.60 | 2.70 | 3.00 | 3.68 | 3.82 | 3.51 | 3.47 | 2.78 | 3.65 | 3.33 | 3.64 | 3.77 | 4.36 | 4.36 | ||||||
| Eli Lilly & Co. | 32.09 | 32.51 | 28.21 | 36.91 | 33.55 | 33.19 | 47.74 | 57.93 | 56.45 | 59.24 | 57.94 | 65.80 | 49.10 | 44.75 | 33.11 | 29.36 | 33.27 | 34.00 | 29.75 | ||||||
| Gilead Sciences Inc. | 16.23 | 13.72 | 7.08 | 8.07 | 6.85 | 6.96 | 6.42 | 7.36 | 6.36 | 5.15 | 4.61 | 4.01 | 4.50 | 4.63 | 4.72 | 4.90 | 4.63 | 3.82 | 3.91 | ||||||
| Johnson & Johnson | 7.61 | 7.35 | 6.70 | 7.12 | 5.86 | 5.20 | 4.79 | 5.30 | 5.69 | 5.37 | 5.20 | 5.48 | 4.92 | 5.79 | 6.00 | 5.37 | 6.04 | 6.01 | 6.36 | ||||||
| Merck & Co. Inc. | 8.26 | 7.57 | 6.09 | 5.82 | 4.04 | 4.12 | 4.32 | 4.99 | 5.73 | 6.53 | 8.00 | 8.68 | 6.35 | 6.96 | 6.38 | 6.07 | 5.63 | 5.12 | 5.44 | ||||||
| Pfizer Inc. | 1.92 | 1.70 | 1.67 | 1.78 | 1.49 | 1.59 | 1.50 | 1.68 | 1.70 | 1.92 | 1.74 | 1.75 | 1.80 | 2.04 | 2.14 | 2.48 | 2.83 | 3.21 | 3.37 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.87 | 2.40 | 2.29 | 2.62 | 2.22 | 1.98 | 2.09 | 2.67 | 3.14 | 4.27 | 3.83 | 3.96 | 3.58 | 3.49 | 3.52 | 3.77 | 3.75 | 3.21 | 3.65 | ||||||
| Vertex Pharmaceuticals Inc. | 6.44 | 5.99 | 5.56 | 6.69 | 6.18 | 5.60 | 7.01 | 7.24 | 8.24 | 8.64 | 5.71 | 6.26 | 5.90 | 5.98 | 6.18 | 5.50 | 6.18 | 6.19 | 5.95 | ||||||
Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
BVPS = Total Thermo Fisher Scientific Inc. shareholders’ equity ÷ No. shares of common stock outstanding
= 54,761,000,000 ÷ 370,515,868 = 147.80
3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= 697.00 ÷ 147.80 = 4.72
5 Click competitor name to see calculations.
The valuation profile exhibits significant volatility in the price-to-book value (P/BV) ratio, driven primarily by fluctuations in the share price against a backdrop of steady growth in book value per share (BVPS).
- Book Value per Share Trend
- A consistent upward trajectory is observed in the book value per share, rising from 104.62 US$ in April 2022 to 147.80 US$ by September 2026. While periodic quarterly declines occurred—most notably in early 2023, 2024, 2025, and 2026—the long-term trend indicates a steady accumulation of equity value.
- Share Price Volatility
- The share price demonstrated substantial variance over the analyzed period. After peaking early in the sequence at 590.26 US$ in July 2022 and reaching a secondary peak of 615.69 US$ in June 2024, the price experienced a significant contraction to a low of 423.55 US$ by March 2025. A strong recovery followed, culminating in a period high of 697.00 US$ in September 2026.
- P/BV Ratio Analysis
- The P/BV ratio mirrored the volatility of the share price, reflecting shifts in market sentiment regarding the company's valuation relative to its assets. The ratio reached a maximum of 5.47 in July 2022 and entered a period of general compression, hitting a cyclical low of 3.24 in March 2025. This trough coincided with the lowest share price in the data set. Subsequently, the ratio rebounded, ending the period at 4.72 in September 2026, suggesting a restoration of the valuation premium as the share price recovered more aggressively than the book value grew.
Overall, the data reveals a divergence between the stable growth of internal book value and the more erratic movements of market valuation. The contraction of the P/BV ratio between 2022 and early 2025 suggests a period of valuation correction, while the subsequent rise indicates renewed market confidence and an expanding premium over the company's net asset value.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?